Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma.
Vela-Ojeda J, Perez-Retiguin FDC, Olivas-Bejarano AC, Garcia-Ruiz Esparza MA, Garcia-Chavez J, Majluf-Cruz A, Reyes-Maldonado E, Montiel-Cervantes LA. Vela-Ojeda J, et al. Among authors: garcia ruiz esparza ma. Leuk Lymphoma. 2021 Apr;62(4):801-809. doi: 10.1080/10428194.2020.1852473. Epub 2020 Dec 7. Leuk Lymphoma. 2021. PMID: 33284055
Important decrease in invariant natural killer T, CD4+ regulatory T cells, CD8+ regulatory T cells, gamma-delta T cells, and CD4+ T lymphocytes in HIV-negative patients with hemophilia.
Vela-Ojeda J, Garcia-Chavez J, Majluf-Cruz A, Reyes-Maldonado E, Garcia-Ruiz Esparza MA, Montiel-Cervantes LA. Vela-Ojeda J, et al. Among authors: garcia ruiz esparza ma. Blood Coagul Fibrinolysis. 2021 Jan 1;32(1):8-15. doi: 10.1097/MBC.0000000000000967. Blood Coagul Fibrinolysis. 2021. PMID: 33148947
Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.
Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, Sánchez-Cortes E, García-Chávez J, Montiel-Cervantes L, Reyes-Maldonado E, Majluf-Cruz A, Mayani H. Vela-Ojeda J, et al. Among authors: garcia ruiz esparza ma. Ann Hematol. 2009 Jan;88(1):59-66. doi: 10.1007/s00277-008-0554-0. Epub 2008 Jul 22. Ann Hematol. 2009. PMID: 18648809
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, Moreno-Lafont M, García-Latorre E, Ramírez-Sanjuan E, Montiel-Cervantes L, Tripp-Villanueva F, García-León LD, Ayala-Sánchez M, Rosas-Cabral A, Aviña-Zubieta JA, Galindo-Rodríguez G, Vadillo-Buenfil M, Salazar-Exaire D. Vela-Ojeda J, et al. Ann Hematol. 2004 May;83(5):295-301. doi: 10.1007/s00277-003-0822-y. Epub 2003 Dec 5. Ann Hematol. 2004. PMID: 15060749
Allogeneic peripheral blood stem cell transplantation using reduced intensity versus myeloablative conditioning regimens for the treatment of leukemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Tripp-Villanueva F, Ayala-Sánchez M, Delgado-Lamas JL, Garcés-Ruiz O, Rubio-Jurado B, Montiel-Cervantes L, Sánchez-Cortés E, García-Chavez J, Xolotl-Castillo M, Rosas-Cabral A, Salazar-Exaire D, Galindo-Rodríguez G, Aviña-Zubieta A. Vela-Ojeda J, et al. Stem Cells Dev. 2004 Oct;13(5):571-9. doi: 10.1089/scd.2004.13.571. Stem Cells Dev. 2004. PMID: 15588514
[CD200 protein, bad prognostic in patients with multiple myeloma].
Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, Pérez-Retiguin F, Reyes-Maldonado E, Maillet D, Montiel-Cervantes LA. Vela-Ojeda J, et al. Among authors: garcia ruiz esparza ma. Rev Med Inst Mex Seguro Soc. 2015 Jul-Aug;53(4):438-43. Rev Med Inst Mex Seguro Soc. 2015. PMID: 26177431 Clinical Trial. Spanish.
Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, García-Latorre E, Moreno-Lafont M, Estrada-García I, Montiel-Cervantes L, Tripp-Villanueva F, Ayala-Sánchez M, García-León LD, Borbolla-Escoboza JR, Mayani H. Vela-Ojeda J, et al. Among authors: garcia ruiz esparza ma. Ann Hematol. 2006 Feb;85(2):113-20. doi: 10.1007/s00277-005-0037-5. Epub 2005 Nov 26. Ann Hematol. 2006. PMID: 16311734
Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chávez J, Tripp-Villanueva F, Sánchez-Cortés E, Ayala-Sánchez M, García-León LD, Montiel-Cervantes L, Rubio-Borja ME. Vela-Ojeda J, et al. Ann Hematol. 2002 Jul;81(7):362-7. doi: 10.1007/s00277-002-0480-5. Epub 2002 Jun 25. Ann Hematol. 2002. PMID: 12185504 Clinical Trial.
18 results